Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOMEDE 2.0 for newly diagnosed DIPG and diffuse midline glioma
2023-506027-29-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) comparing Radiotherapy + Afinitor with Radiotherapy + ONC201 (2 arms). Primary endpoint: Progression-free survival from randomization. Planned start Oct 2014; status: authorised.
02
Drugs
everolimusdordaviprone
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on 2023-506027-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506027-29-00.